Jamie Dimon says he still sees a recession on the horizon

Jamie Dimon says he still sees a recession on the horizon


Key Points
  • JPMorgan Chase CEO Jamie Dimon said Wednesday he still believes that the odds of a “soft landing” for the economy are around 35% to 40%, making recession the most likely scenario in his mind.
  • When asked by CNBC’s Leslie Picker if he had changed his view from earlier this year that markets were too optimistic on recession risks, Dimon said the odds were “about the same” as his earlier call.
  • Dimon added he was “a little bit of a skeptic” that the Federal Reserve can bring inflation down to its 2% target because of future spending on the green economy and military.



Source

Blackrock’s iShares bitcoin fund sees record exodus as crypto heads for worst month since 2022
Finance

Blackrock’s iShares bitcoin fund sees record exodus as crypto heads for worst month since 2022

Crypto World Blackrock’s iShares bitcoin fund sees record exodus as crypto heads for worst month since 2022 Published Mon, Nov 24 20257:19 PM ESTUpdated 13 Min Ago Liz Napolitano@LizKNapolitano WATCH LIVE Source

Read More
Stocks making the biggest moves after hours: Zoom, Semtech, Agilent Technologies, Sandisk and more
Finance

Stocks making the biggest moves after hours: Zoom, Semtech, Agilent Technologies, Sandisk and more

Check out the companies making headlines in after-hours trading. Zoom Communications — The work services stock jumped almost 4% after posting stronger-than-expected third-quarter earnings and upbeat full-year guidance. Zoom earned $1.52 per share excluding items on $1.23 billion in revenue, while analysts polled by LSEG penciled in $1.44 a share and $1.21 billion, respectively. The […]

Read More
Stocks making the biggest moves midday: Novo Nordisk, Inspire Medical, Tesla, Tegna, Oscar Health and more
Finance

Stocks making the biggest moves midday: Novo Nordisk, Inspire Medical, Tesla, Tegna, Oscar Health and more

Check out the companies making the biggest moves midday: Novo Nordisk — The Danish pharmaceutical company’s trial for Alzheimer’s disease failed to meet its main goal of slowing the disease’s progression. Shares tumbled nearly 6%. Inspire Medical Systems — The maker of an obstructive sleep apnea treatment will benefit from Friday’s decision by the Centers […]

Read More